Literature DB >> 26339368

Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer.

Encheng Zhou1, Qing Huang2, Ji Wang1, Chengfeng Fang1, Leilei Yang1, Min Zhu1, Jianhui Chen1, Lihua Chen1, Milian Dong1.   

Abstract

Tim-3 (T cell immunoglobulin and mucin domain 3), belonging to the member of the novel Tim family, has been confirmed that it plays a critical negative role in regulating the immune responses against viral infection and carcinoma. Recently, it has also been reported that the over-expression of Tim-3 is associated with poor prognosis in solid tumors. However, the role of Tim-3 in colorectal cancer remains largely unknown. In the current study, we aim to investigate the expression of Tim-3 in colorectal carcinoma and discuss the relationship between Tim-3 expression and colon cancer prognosis, thus speculating the possible role of Tim-3 in colon cancer progression. Colon cancer tissues and paired normal tissue were obtained from 201 patients with colon cancer for preparation of tissue microarray. Tim-3 expression was evaluated by immunohistochemical staining. The Tim-3 expression level was evaluated by q-RT-PCR, western blot and immunocytochemistry in four colon cancer cell lines (HT-29, HCT116, LoVo, SW620). Tim-3 was expressed in 92.5% tumor tissue samples and 86.5% corresponding normal tissue samples. Expression of Tim-3 was significantly higher in tumor tissues than in normal tissues (P < 0.0001). Tim-3 expression in colon cancer tissues is in correlation with colon cancer lymphatic metastasis and TNM (P < 0.0001). Multivariate analysis demonstrated that Tim-3 expression could be a potential independent prognostic factor for colon cancer patients (P < 0.0001). Kaplan-Meier survival analysis result showed that patients with higher Tim-3 expression had a significantly shorter survival time than those with lower Tim-3 expression patients. Our results indicated that Tim-3 might participate in the tumorgenesis of colon cancer and Tim-3 expression might be a potential independent prognostic factor for patients with colorectal cancer.

Entities:  

Keywords:  Tim-3; colon cancer; overall survival; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26339368      PMCID: PMC4555696     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  30 in total

Review 1.  The role of chemokine receptors in primary, effector, and memory immune responses.

Authors:  F Sallusto; C R Mackay; A Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma.

Authors:  Y Hasegawa; S Takanashi; Y Kanehira; T Tsushima; T Imai; K Okumura
Journal:  Cancer       Date:  2001-03-01       Impact factor: 6.860

3.  The dimensions of the CRC problem.

Authors:  L V Karsa; T A Lignini; J Patnick; R Lambert; C Sauvaget
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-08       Impact factor: 3.043

4.  Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response.

Authors:  Hui Geng; Gui-Mei Zhang; Dong Li; Hui Zhang; Ye Yuan; Han-Gang Zhu; Han Xiao; Ling-Fei Han; Zuo-Hua Feng
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

5.  Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion.

Authors:  Xiaoyuan Huang; Xiangyang Bai; Yang Cao; Jingyi Wu; Mei Huang; Duozhuang Tang; Si Tao; Tao Zhu; Yanling Liu; Yang Yang; Xiaoxi Zhou; Yanxia Zhao; Mingfu Wu; Juncheng Wei; Daowen Wang; Gang Xu; Shixuan Wang; Ding Ma; Jianfeng Zhou
Journal:  J Exp Med       Date:  2010-02-22       Impact factor: 14.307

6.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

7.  Prognostic implication of TIM-3 in clear cell renal cell carcinoma.

Authors:  J Yuan; B Jiang; H Zhao; Q Huang
Journal:  Neoplasma       Date:  2014       Impact factor: 2.575

8.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

9.  Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC.

Authors:  Xuewei Zhuang; Xiaoning Zhang; Xiyan Xia; Cuijuan Zhang; Xiaohong Liang; Lifen Gao; Xin Zhang; Chunhong Ma
Journal:  Am J Clin Pathol       Date:  2012-06       Impact factor: 2.493

View more
  39 in total

1.  Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment.

Authors:  Paweł Łaniewski; Haiyan Cui; Denise J Roe; Dana M Chase; Melissa M Herbst-Kralovetz
Journal:  NPJ Precis Oncol       Date:  2020-08-03

2.  Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.

Authors:  Guanzhang Li; Zheng Wang; Chuanbao Zhang; Xing Liu; Jinquan Cai; Zhiliang Wang; Huimin Hu; Fan Wu; Zhaoshi Bao; Yanwei Liu; Liang Zhao; Tingyu Liang; Fan Yang; Ruoyu Huang; Wei Zhang; Tao Jiang
Journal:  Oncoimmunology       Date:  2017-07-28       Impact factor: 8.110

Review 3.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

4.  Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis.

Authors:  Hualin Zhang; Yang Song; Huimin Yang; Zhiyan Liu; Lifen Gao; Xiaohong Liang; Chunhong Ma
Journal:  Oncogene       Date:  2018-02-16       Impact factor: 9.867

Review 5.  Immunotherapy in colorectal cancer: for the select few or all?

Authors:  Sukeshi Patel Arora; Devalingam Mahalingam
Journal:  J Gastrointest Oncol       Date:  2018-02

Review 6.  Tim-3 and its role in regulating anti-tumor immunity.

Authors:  Madhumita Das; Chen Zhu; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

7.  Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells.

Authors:  Yizi Cong; Yuxin Cui; Shiguang Zhu; Jianqiao Cao; Haidong Zou; Tracey A Martin; Guangdong Qiao; Wenguo Jiang; Zhigang Yu
Journal:  Chin J Cancer Res       Date:  2020-10-31       Impact factor: 5.087

8.  Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.

Authors:  Keiko Nagahara; Tomohiro Arikawa; Souichi Oomizu; Keiichi Kontani; Atsuya Nobumoto; Hiroaki Tateno; Kota Watanabe; Toshiro Niki; Shigeki Katoh; Minoru Miyake; Syun-Ichiro Nagahata; Jun Hirabayashi; Vijay K Kuchroo; Akira Yamauchi; Mitsuomi Hirashima
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

9.  A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186.

Authors:  Cameron J Herting; Matthew R Farren; Yan Tong; Ziyue Liu; Bert O'Neil; Tanios Bekaii-Saab; Anne Noonan; Christopher McQuinn; Thomas A Mace; Walid Shaib; Christina Wu; Bassel F El-Rayes; Safi Shahda; Gregory B Lesinski
Journal:  Cancer Immunol Immunother       Date:  2021-06-23       Impact factor: 6.968

Review 10.  Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution.

Authors:  Veronica Mollica; Vincenzo Di Nunno; Lidia Gatto; Matteo Santoni; Alessia Cimadamore; Liang Cheng; Antonio Lopez-Beltran; Rodolfo Montironi; Salvatore Pisconti; Nicola Battelli; Francesco Massari
Journal:  Clin Drug Investig       Date:  2019-06       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.